Evidence map›Paper›PMID 26392558›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Ubiquitin ligase Siah2 regulates RevErbα degradation and the mammalian circadian clock.

Jason P DeBruyne, Julie E Baggs, Trey K Sato, John B Hogenesch

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 40 citations in OpenAlex.

  1. Circadian rhythms and lung cancer biology and immunotherapy: Emerging opportunities and challenges.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Timed use of cardiac glycoside protects the heart.Nature cardiovascular research · 2022
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Systems Chronotherapeutics.Pharmacological reviews · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Jason P DeBruyneNeuroscience Institute, Department of Pharmacology and Toxicology, Morehouse School of Medicine, Atlanta, GA 30310; jdebruyne@msm.edu hogenesc@mail.med.upenn.edu.
Julie E BaggsNeuroscience Institute, Department of Pharmacology and Toxicology, Morehouse School of Medicine, Atlanta, GA 30310;
Trey K SatoDepartment of Pharmacology, Penn Genome Frontiers Institute, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA, 19104.
John B HogeneschDepartment of Pharmacology, Penn Genome Frontiers Institute, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA, 19104 jdebruyne@msm.edu hogenesc@mail.med.upenn.edu.
Morehouse School of Medicine · USTranslational Therapeutics (United States) · USUniversity of Pennsylvania · US

Funding

Morehouse School of Medicine Center of Excellence Research Endowment ProgramS21MD000101 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI MONTGOMERY-RICE, VALERIE C. · 2001 to 2015
$74.3M
Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Rebecca A Simmons · 2006 to 2026
$35.3M
TRANSPLANTATION OF EXOSOMES FROM HYPOXIA-PRECONDITIONED ADIPOSE-DERIVED STEM CELLS PROMOTES ANGIOGENESIS IN ISCHEMIC HEARTG12MD007602 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI BOND, VINCENT C · 2012 to 2017
$18.4M
Chemical and Genetic Manipulation of Circadian SystemsP50MH074924 · NIMH · NORTHWESTERN UNIVERSITY · PI TAKAHASHI, JOSEPH S · 2005 to 2009
$10.4M
Molecular, Cellular and Physiological Mechanisms of the Mammalian Circadian ClockR01NS054794 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI HOGENESCH, JOHN B, LIU, ANDREW C. · 2007 to 2022
$8.1M
Program Evaluation - Internal & External U54NS083932 · NINDS · MOREHOUSE SCHOOL OF MEDICINE · PI MACLEISH, PETER RAYMOND · 2013 to 2017
$7.7M
Degradation Mechanisms of Mammalian Circadian Clock ProteinsSC1GM109861 · NIGMS · MOREHOUSE SCHOOL OF MEDICINE · PI DEBRUYNE, JASON P · 2014 to 2017
$1.4M
NIEHS NIH HHS P30 ES013508NIGMS NIH HHS SC1 GM109861NIMHD NIH HHS 8G12MD007602NIMHD NIH HHS G12 MD007602NIMHD NIH HHS S21 MD000101NIMH NIH HHS MH074924NIMH NIH HHS P50 MH074924NINDS NIH HHS R01 NS054794NINDS NIH HHS U54 NS083932
6 · The paper itself

Abstract

Regulated degradation of proteins by the proteasome is often critical to their function in dynamic cellular pathways. The molecular clock underlying mammalian circadian rhythms relies on the rhythmic expression and degradation of its core components. However, because the tools available for identifying the mechanisms underlying the degradation of a specific protein are limited, the mechanisms regulating clock protein degradation are only beginning to be elucidated. Here we describe a cell-based functional screening approach designed to quickly identify the ubiquitin E3 ligases that induce the degradation of potentially any protein of interest. We screened the nuclear hormone receptor RevErbα (Nr1d1), a key constituent of the mammalian circadian clock, for E3 ligases that regulate its stability and found Seven in absentia2 (Siah2) to be a key regulator of RevErbα stability. Previously implicated in hypoxia signaling, Siah2 overexpression destabilizes RevErbα/β, and siRNA depletion of Siah2 stabilizes endogenous RevErbα. Moreover, Siah2 depletion delays circadian degradation of RevErbα and lengthens period length. These results demonstrate the utility of functional screening approaches for identifying regulators of protein stability and reveal Siah2 as a previously unidentified circadian clockwork regulator that mediates circadian RevErbα turnover.

Indexed as

AnimalsBlotting, WesternCell LineCell Line, TumorCells, CulturedCircadian ClocksEmbryo, MammalianFibroblastsGene ExpressionHumansMiceMicroscopy, FluorescenceNuclear ProteinsNuclear Receptor Subfamily 1, Group D, Member 1ProteolysisReverse Transcriptase Polymerase Chain ReactionNR1D1 protein, humanNuclear ProteinsNuclear Receptor Subfamily 1, Group D, Member 1Seven in Absentia ProteinsUbiquitin-Protein Ligasescircadian clockRevErbα/Nr1d1Siah2ubiquitin ligase screen

Identifiers

PMID26392558
PMCPMC4603519
OpenAlexW1851633531

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.